Abstracts tagged "juvenile dermatomyositis"

Abstract Number: 092 • 2023 Pediatric Rheumatology Symposium
Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls
Christopher Costin¹, Gabrielle Morgan², Lutfiyya Muhammad³, Amer Khojah⁴, Marisa Klein-Gitelman¹, Yvonne Lee⁵ and Lauren Pachman⁶, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Umm Al-Qura University, Makkah, Saudi Arabia, ⁵Northwestern University, Chicago, IL, ⁶Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Patients with JDM are at increased risk of infection due to increased aspiration risk and immunosuppression. Procalcitonin (PCT) is a biomarker of infection, that…
Abstract Number: 049 • 2023 Pediatric Rheumatology Symposium
What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study
Kaveh Ardalan¹, Rebecca Fillipo¹, Christina ZIgler², Audrey Ward¹, Jeffrey Dvergsten³, Ann Reed¹, Alison Manning¹, Gary Maslow¹, Brian Feldman⁴, Ashley Danguecan⁵, Sarah Mossad⁵, Luana Flores Pereira⁵, Susan Shenoi⁶, Stacey Haynes⁷, Joanna Patten⁷ and Andrea Knight⁵, ¹Duke University School of Medicine, Durham, NC, ²Duke, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Seattle Children's Hospital, Seattle, WA, ⁷Seattle Childrens Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile myositis (JM) patients report high rates of emotional distress but qualitative studies suggest challenges accessing high quality mental health care. We present survey…
Abstract Number: 0775 • ACR Convergence 2021
Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
Amer Khojah¹, Arya Kadakia², Christina Charles-Schoeman³, Jacob Spitznagle⁴, Jennifer Wang³, Ani Shahbazian³, Gabrielle Morgan⁵ and Lauren Pachman⁶, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann and Robert H. Lurie Children’s Hospital, Chicago, IL, ³Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, New York, NY, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is the most common inflammatory myopathy of childhood and is characterized by chronic inflammation targeting muscle and skin. Older patients who…
Abstract Number: 0978 • ACR Convergence 2021
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
Amer Khojah¹, Gabrielle Morgan² and Lauren Pachman³, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…
Abstract Number: 1907 • ACR Convergence 2021
Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study
Ameera Bukhari¹, Amer Khojah², Wilfredo Marin³, Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric inflammatory myopathy with a complex pathophysiology. Previously our group showed a significant increase in Otoferlin mRNA expression…
Abstract Number: 021 • 2020 Pediatric Rheumatology Symposium
Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies
Dawn Wahezi ¹, Natalia Vasquez Canizares ², Gabriel Tarshish ² and Megan Colwell², ¹Children's Hospital at Montefiore, Bronx, ²Children's Hospital at Montefiore, new york
Background/Purpose: The presence of myositis specific autoantibodies (MSA) and myositis associated antibodies (MAA) has been associated with specific clinical phenotypes, various organ involvement and disease…
Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium
Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Sonia Savani¹, Natasha Ruth ², Paul Nietert ¹, Gabrielle Morgan ³, Mileka Gilbert ¹ and Lauren Pachman ⁴, ¹Medical University of South Carolina, Charleston, South Carolina, ²Medical University South Carolina, Charleston, South Carolina, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…
Abstract Number: 082 • 2020 Pediatric Rheumatology Symposium
Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis
Sara Sabbagh¹, Iago Pinal-Fernandez ², Maria Casal-Dominguez ³, Frederick W. Miller ⁴, Lisa G. Rider ⁵, Andrew Mammen ³ and Lisa Christopher-Stine ⁶, ¹NIH/NIAMS, Bethesda, ²National Institutes of Health, Bethesda, ³NIH, Bethesda, ⁴Bethesda, ⁵NIEHS, NIH, Garrett Park, ⁶Johns Hopkins University, Baltimore
Background/Purpose: We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in both juvenile-(JM) and adult-onset myositis cohorts and investigated phenotype differences between juvenile and adult myositis…
Abstract Number: 105 • 2020 Pediatric Rheumatology Symposium
Discovering the Implications of Adiposity in Juvenile Dermatomyositis
Vy Do¹, Chanhee Jo ², Jaclyn Albin ¹, Tracey Wright ¹, Julie Fuller ³ and Una Makris ¹, ¹UT Southwestern Medical Center, Dallas, ²Texas Scottish Rite Hospital, Dallas, ³UT Southwestern Medical Center, Frisco
Background/Purpose: Obesity and pro-inflammatory cytokines produced by adipocytes have been linked to many outcomes including disease severity, treatment response, and disease progression in several autoimmune…
Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Jessica Neely¹, Adam Huber ² and Susan Kim ³ for the CARRA investigators, ¹University of California, San Francisco, San Francisco, California, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³University of California, San Francisco, San Francisco
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
Abstract Number: 125 • 2020 Pediatric Rheumatology Symposium
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
Kaveh Ardalan¹, Alison Manning ¹, Brian Feldman ², Gary Maslow ¹ and Andrea Knight ³, ¹Duke University Medical Center, Durham, ²The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada
Background/Purpose: Juvenile myositis (JM) negatively affects health-related quality of life due to chronic weakness, skin/muscle damage, multiorgan dysfunction, and side effects of immunosuppression. While JM’s…
Abstract Number: 156 • 2020 Pediatric Rheumatology Symposium
Metabolic Profiling in Juvenile Dermatomyositis
Jeffrey Dvergsten¹, Olga Ilkayeva ², Lawrence Landerman ², Michael Muehlbauer ³, David Pisetsky ⁴, Ann Reed ³ and Kim Huffman ⁵, ¹Duke University Hospital, Hillsborough, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University Medical Center, Durham, ⁵Durham
Background/Purpose: Investigators have made significant progress piecing together pathogenic mechanisms of juvenile dermatomyositis (DM). However, this remains an incomplete puzzle, and optimal approaches to diagnosing,…
Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
Lucila Pereira¹, Agatha Nogueira Previdelli ², Rosana Gomes de Torres Rossi ², Wellington Douglas Rodrigues ³, Fernado Luiz Affonso Fonseca ³, Claudio Len ⁴, Roseli Oselka Saccardo Sarni ³ and Maria Teresa Terreri ⁴, ¹Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Sao Judas Tadeu University, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Sao Paulo, Brazil
Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…
Abstract Number: 1924 • 2019 ACR/ARP Annual Meeting
Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom
Polly Livermore¹ and Lucy Wedderburn ², ¹ICH/UCL, Arlesey, United Kingdom, ²ICH/UCL, London, United Kingdom
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare, autoimmune inflammatory condition primarily affecting the muscles and skin. With a mean age of onset of 7 years…
Abstract Number: 2106 • 2019 ACR/ARP Annual Meeting
Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Sara Sabbagh¹, Jessica Neely ², Jamie Lai ³, Anjali Sura ⁴, Kelly Rouster-Stevens ⁵, Svetlana Lvovich ⁶, Tara McGrath ⁷, Lori Tucker ⁸, Heinrike Schmeling ⁹, Jordan Roberts ¹⁰, Lisa G. Rider ¹¹ and Susan Kim ², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Pediatrics, University of Colorado School of Medicine, Division of Pediatric Rheumatology, Children’s Hospital Colorado, Aurora, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Section of Rheumatology, Department of Pediatrics, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada, ⁸British Columbia Children’s Hospital, Vancouver, Canada, ⁹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Boston Children’s Hospital, Harvard Medical School, Boston, MD, ¹¹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Approximately 6% of adults with idiopathic inflammatory myopathy (IIM) develop Pneumocystis jirovecii pneumonia (PJP), and PJP confers higher mortality in IIM patients compared to…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].